The efficacy of Ceftriaxone at postsymptomatic stages in the Sacs–/– mouse model encourages a future translation in clinics, as most patients with ARSACS are diagnosed only after the onset of gait abnormalities. Here, SACS is linked to Autosomal recessive spastic ataxia of Charlevoix-Saguenay.